The combination of these two agents resulted in a synergistic effect, with the anti-PD-L1 nanobodies enhancing T-cell activation and the IL-12 further boosting the immune response, leading to significant tumor regression in mouse models 162. The gene discussed is CD274; the disease is neoplasm.